Related to this topic: Leaflets | Support | Patient+ | UK Guidelines | Weblinks | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Neuropathic Pain and its Management

Neuropathic pain is defined by the International Association for the Study of Pain (IASP) as pain arising from inflammation or injury to the peripheral or central nervous system, or from dysfunction of the nervous system.1
The terminology becomes a little confused, because the term 'neuropathic pain' was previously confined to peripheral nerve pain only. It is now used for pain of central origin as well (e.g.lateral medullary syndrome), and the addition of the concept of dysfunction allows for the inclusion of reflex sympathetic dystrophy.

The term 'neurogenic pain' is also sometimes used, which embraces both peripheral and central causes.

Clinical Features2
  • The discomfort is usually of a chronic nature and may be described by the patient as a burning sensation, a sharp, stabbing or shooting pain, or 'like an electric shock'.
  • Other features may include:
    • Allodynia - seemingly harmless stimuli such as light touch can provoke pain.
    • Hyperpathia - a short episode of discomfort causes prolonged severe pain.
    • Hyperalgesia - discomfort which would otherwise be mild is felt as severe pain.
Prevalence
  • One study suggests that approximately 8% of the UK population suffer from neuropathic pain.3
  • This is consistent with a rather more selective group of patients attending a Neurology Clinic in Spain. Of the 1,972 patients attending, 7.95% were diagnosed as having neuropathic pain.4

Aetiology1,5

Peripheral Causes

Central Causes

Mononeuropathies and multiple mononeuropathies

  • Diabetic mononeuropathy and amyotrophy
  • Trauma: painful scars, compression, transection of a nerve, post-thoracotomy
  • Neuralgic amyotrophy
  • Damage to nerve plexi (plexopathy) from malignancy or radiation
  • Connective tissue disease
  • Rare causes - Trench foot (damage due to cold exposure over several days), Borreliosis
Polyneuropathies

  • Metabolic/Nutritional:

    • Diabetic
    • Alcoholic
    • Amyloid
    • Pellagra
    • Beriberi
    • Cuban neuropathy (usual cause B-group vitamin deficiency)
    • Burning Feet Syndrome
    • Tanzanian neuropathy (may be Coxsackie infection)6
    • Strachan's (Jamaican) neuropathy (orogenital ulceration, sensory neuropathy, ambylopia - cause unknown)7

  • Drugs/Toxic:

    • Nitrofurantoin
    • Isoniazid
    • Vincristine, Cisplatin, Arsenic
    • Thallium
    • Clioquinol
    • Disulfiram

  • Infective

  • Heriditary

    • Fabry's disease
    • Dominantly inherited sensory neuropathy/ HSAN (Hereditary Sensory and Autonomic Neuropathy (an inherited sensorimotor axonal neuropathy)7

  • Malignancy:

  • Idiopathic small fibre neuropathy

Management
  • The treatment of the underlying causative condition is central to the management of neuropathic pain but is outside the scope of this record. Neuropathy caused by mechanical pressure for example may require surgical and other interventional procedures.
  • The main role of the GP in the management of neuropathic pain is in the control of symptoms where the underlying cause is medical, where the condition is of a chronic, recurring or acute self-limiting nature, or whilst awaiting specialist intervention.

Non-pharmacological measures

  • Psychological techniques - there are no meta-analyses in the management of neuropathic pain per se, but CBT performed well in patients who had chronic pain from various causes.10 The trials that have been done indicate that CBT and other psychological techniques may be helpful in some forms of neuropathic pain.11,12
  • Patient education - this is often quoted as a strategy, though the evidence-base is lacking.13 Logic would dictate however that an informed patient is more able to be involved in decisions about their care, and this is certainly relevant in terms of compliance.14
  • Electrical stimulation - interpretation of systematic trials are difficult due to differing methodologies.15 However, transcutaneous electrical nerve stimulation (TENS) performs consistently well compared to placebo.16,17
  • Acupuncture - systematic evidence to support its use in neuropathic pain is lacking.18 There is some evidence that percutaneous nerve stimulation (PENS), which combines the techniques of acupuncture and TENS,may be helpful for some patients with diabetic neuropathy.19

Pharmacological Measures

Most controlled trials have focussed on the relief of pain, rather than the sometimes more distressing symptoms of allodynia or hyperalgesia, or the effect of treatment on the quality of life.20 This makes a comparative interpretation of the available treatments difficult.21,22The general consensus, however, supports the use of the following drugs:23

  • Non-opioid analgesics and NSAIDs - these perform well against placebo, particularly in diabetic neuropathy, but most patients require more targeted treatments.24,25
  • Tricyclic antidepressants - amitriptyline is the most frequently prescribed (unlicensed use), initially 10-25mg nocte. The dose may be increased gradually to 75mg daily if required. Higher doses should be instituted under specialist supervision .A systematic review showed no difference between the tricyclics regarding effectiveness, but nortriptyline, also given initially at 10-25mg at night, may cause less side effects.26,27 There is limited evidence that SSRIs are effective.28
  • Anti-convulsants - both gabapentin and pregabalin are licensed for the treatment of neuropathic pain.29,30 The optimum dose of gabapentin for this indication would seem to be 1800-3600mg daily.29 and of pregabalin 100-600mg daily.31 Both drugs can cause dizziness, drowsiness, and peripheral oedema. However, trials suggest that pregabalin is effective at lower doses, and therefore has less potential than gabapentin for causing adverse effects at a symptom-controlling dose.32
  • Opioids - may produce only a partial response, but may be useful where other methods fail.27 There is systematic evidence to support the use of tramadol33, and oxycodone.34 There are small randomised trials supporting the use of methadone, but larger systematic reviews are required.35
  • Topical creams - capsaicin cream is licensed for neuropathic pain. It can be applied three to four times a day. It should not be used on broken or inflamed skin. It can cause irritation at the site of application.27,36 Systematic review suggests it may be useful as an adjunct for a small number of patients unresponsive to other treatment.37
  • Specialist-instituted treatments - these include lidocaine27,38 and ketamine, both of which are given intravenously (unlicensed use).39 Sodium valproate and phenytoin are now generally reserved for specialist use,40 and corticosteroids are sometimes given to relieve pressure in compression neuropathy.27 Intrathecal injections and nerve blocking techniques are other options, but relief tends to be temporary.41

Referral to a Specialist in Pain Management

This should be considered whenever there is doubt about the diagnosis of neuropathic pain, if there has been inadequate response to treatment, or if other treatments not available in primary care are required (e.g. unlicensed drugs, physical therapy such as nerve blocks, etc).


Document references
  1. Scadding JAdvances in Clinical Neuroscience and Rehabilitation 2003;3(2)
  2. IASP Pain Terminology
  3. Leeds Pallium Research Group Newsletter - October 2005
  4. Carneado-Ruiz J, Morera-Guitart J, Alfaro-Saez A, et al; ; Rev Neurol. 2005 Dec 1-15;41(11):643-8. [abstract]
  5. Epidemic Neuropathy - Tanzania (Coast)
  6. Oluwole OS, Onabolu AO, Link H, et al; Persistence of tropical ataxic neuropathy in a Nigerian community.; J Neurol Neurosurg Psychiatry. 2000 Jul;69(1):96-101. [abstract]
  7. Neuropathy, Hereditary Sensory And Autonomic, Type I; Hsan1
  8. National Institute of Neurological Diseases and Stroke; Lateral Medullary Syndrome
  9. SyrinxThe Merck Manual of Diagnosis and Therapy Section 14. Neurologic Disorders Chapter 182. Spinal Cord Disorders
  10. Morley S, Eccleston C, Williams A; Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache.; Pain. 1999 Mar;80(1-2):1-13. [abstract]
  11. Chen H, Lamer TJ, Rho RH, et al; Contemporary management of neuropathic pain for the primary care physician.; Mayo Clin Proc. 2004 Dec;79(12):1533-45. [abstract]
  12. Evans S, Fishman B, Spielman L, et al; Randomized trial of cognitive behavior therapy versus supportive psychotherapy for HIV-related peripheral neuropathic pain.; Psychosomatics. 2003 Jan-Feb;44(1):44-50. [abstract]
  13. Arnstein P; Chronic neuropathic pain: issues in patient education.; Pain Manag Nurs. 2004 Dec;5(4 Suppl 1):34-41. [abstract]
  14. Gilron I, Bailey J, Weaver DF, et al; Patients' attitudes and prior treatments in neuropathic pain: a pilot study.; Pain Res Manag. 2002 Winter;7(4):199-203. [abstract]
  15. Fargas-Babjak, Angelica M.D. Acupuncture, Transcutaneous Electrical Nerve Stimulation, and Laser Therapy in Chronic Pain. Clinical Journal of Pain. Etiology, Prevention, Treatment, and Disability Management of Chronic Pain. 17(4) Supplement:S105-S113, December 2001.
  16. Cheing GL, Luk ML; Transcutaneous electrical nerve stimulation for neuropathic pain.; J Hand Surg [Br]. 2005 Feb;30(1):50-5. [abstract]
  17. Bohm E; Transcutaneous electrical nerve stimulation in chronic pain after peripheral nerve injury.; Acta Neurochir (Wien). 1978;40(3-4):277-83. [abstract]
  18. Hempenstall K, Nurmikko TJ, Johnson RW, et al; Analgesic therapy in postherpetic neuralgia: a quantitative systematic review.; PLoS Med. 2005 Jul;2(7):e164. Epub 2005 Jul 26. [abstract]
  19. Hamza MA, White PF, Craig WF, et al; Percutaneous electrical nerve stimulation: a novel analgesic therapy for diabetic neuropathic pain.; Diabetes Care. 2000 Mar;23(3):365-70. [abstract]
  20. Bandolier - Relief of Chronic Non-Malignant Pain
  21. McQuay HJ, Tramer M, Nye BA, et al; A systematic review of antidepressants in neuropathic pain.; Pain. 1996 Dec;68(2-3):217-27. [abstract]
  22. Finnerup NB, Otto M, McQuay HJ, et al; Algorithm for neuropathic pain treatment: an evidence based proposal.; Pain. 2005 Dec 5;118(3):289-305. Epub 2005 Oct 6. [abstract]
  23. No authors listed; Drug treatment of neuropathic pain. Drug Ther Bull. 2000 Dec;38(12):89-93. [abstract]
  24. Duby JJ, Campbell RK, Setter SM, et al; Diabetic neuropathy: an intensive review.; Am J Health Syst Pharm. 2004 Jan 15;61(2):160-73; quiz 175-6. [abstract]
  25. Cohen KL, Harris S; Efficacy and safety of nonsteroidal anti-inflammatory drugs in the therapy of diabetic neuropathy.; Arch Intern Med. 1987 Aug;147(8):1442-4. [abstract]
  26. Antidepressants in neuropathic pain Bandolier, 1999
  27. British National Formulary British Medical Association and Royal Pharmaceutical Society of Great Britain. London.
  28. Saarto T, Wiffen PJ; Antidepressants for neuropathic pain.; Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005454. [abstract]
  29. Bennett MI, Simpson KH; Gabapentin in the treatment of neuropathic pain.; Palliat Med. 2004 Jan;18(1):5-11. [abstract]
  30. Freynhagen R, Strojek K, Griesing T, et al; Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens.; Pain. 2005 Jun;115(3):254-63. Epub 2005 Apr 18. [abstract]
  31. Backonja M, Glanzman RL; Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials.; Clin Ther. 2003 Jan;25(1):81-104. [abstract]
  32. McAuley D How does pregabalin compare to gabapentin in the treatment of neuropathic pain? GlobalRPh.com
  33. Duhmke RM, Cornblath DD, Hollingshead JR; Tramadol for neuropathic pain.; Cochrane Database Syst Rev. 2004;(2):CD003726. [abstract]
  34. Kalso E; Oxycodone.; J Pain Symptom Manage. 2005 May;29(5 Suppl):S47-56. [abstract]
  35. Sandoval JA, Furlan AD, Mailis-Gagnon A; Oral methadone for chronic noncancer pain: a systematic literature review of reasons for administration, prescription patterns, effectiveness, and side effects.; Clin J Pain. 2005 Nov-Dec;21(6):503-12. [abstract]
  36. Sawynok J; Topical analgesics in neuropathic pain.; Curr Pharm Des. 2005;11(23):2995-3004. [abstract]
  37. Mason L, Moore RA, Derry S, et al; Systematic review of topical capsaicin for the treatment of chronic pain.; BMJ. 2004 Apr 24;328(7446):991. Epub 2004 Mar 19. [abstract]
  38. Challapalli V, Tremont-Lukats IW, McNicol ED, et al; Systemic administration of local anesthetic agents to relieve neuropathic pain.; Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003345. [abstract]
  39. Kvarnstrom A, Karlsten R, Quiding H, et al; The analgesic effect of intravenous ketamine and lidocaine on pain after spinal cord injury.; Acta Anaesthesiol Scand. 2004 Apr;48(4):498-506. [abstract]
  40. Wiffen P, Collins S, McQuay H, et al; Anticonvulsant drugs for acute and chronic pain.; Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001133. [abstract]
  41. Ahmad M, Goucke CR; Management strategies for the treatment of neuropathic pain in the elderly.; Drugs Aging. 2002;19(12):929-45. [abstract]

Internet and further reading AcknowledgementsEMIS is grateful to Dr Laurence Knott for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2007.
DocID: 466
Document Version: 2
DocRef: bgp25146
Last Updated: 3 Aug 2007
Review Date: 2 Aug 2008






















Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site














Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page